The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pyrotinib dose escalation|DRUG: Pyrotinib dose normal
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Collaborators: Zhongda Hospital|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Jingjiang People's Hospital|Yancheng First People's Hospital|Affiliated Hospital of Jiangnan University|Affiliated Hospital of Nantong University|Anhui Provincial Cancer Hospital|Huai'an First People's Hospital|The Affiliated Hospital of Xuzhou Medical University|Suzhou Municipal Hospital|Affiliated Hospital of Jiangsu University